QTc interval lengthening in first-episode schizophrenia (FES) patients in the earliest stages of antipsychotic treatment

Schizophrenia Research

Volumn 179, Issue , 2017, Pages 70-74

  Zhai, Desheng ^a   Zhang, Ruiling ^a   Lang, Yan ^b   Dong, Gaopan ^a   Liu, Yijun ^a   Zhou, Dushuang ^a   Cui, Taizhen ^a   Zhang, Wenxi ^a   Zhao, Ying ^a   Wang, Xin ^c   Yang, Yuxin ^d  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

^d THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Antipsychotics; First episode schizophrenia; QTc interval; Short term

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; ANTIPSYCHOTIC THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHEMOTHERAPY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; DRUG EXPOSURE; ELECTROCARDIOGRAM; FEMALE; FIRST EPISODE SCHIZOPHRENIA; HEART DISEASE; HIGH RISK POPULATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONOTHERAPY; PRIORITY JOURNAL; QTC INTERVAL LENGTHENING; RETROSPECTIVE STUDY; SAMPLE SIZE; SCHIZOPHRENIA; SEX DIFFERENCE; THERAPY; TREATMENT DURATION; TREND STUDY; ADOLESCENT; CHEMICALLY INDUCED; ELECTROCARDIOGRAPHY; LONG QT SYNDROME; MIDDLE AGED; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHILD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS; YOUNG ADULT;

EID: 84992315302     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.10.006     Document Type: Article

References (36)

1. Agelink, M.W., Majewski, T., Wurthmann, C., Lukas, K., Ullrich, H., Linka, T., Klieser, E., Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J. Clin. Psychopharmacol. 21:1 (2001), 8–13.
2. Bär, K.J., Letzsch, A., Jochum, T., Wagner, G., Greiner, W., Sauer, H., Loss of efferent vagal activity in acute schizophrenia. J. Psychiatr. Res. 39 (2005), 519–527.
3. Blom, M.T., Bardai, A., van Munster, B.C., Nieuwland, M.I., de Jong, H., van Hoeijen, D.A., Spanjaart, A.M., de Boer, A., de Rooij, S.E., Tan, H.L., Differential changes in QTc duration during in-hospital haloperidol use. PLoS One, 6(9), 2011, e23728.
4. Chang, H.A., Chang, C.C., Tzeng, N.S., Kuo, T.B., Lu, R.B., Huang, S.Y., Cardiac autonomic dysregulation in acute schizophrenia. Acta Neuropsychiatr. 25 (2013), 155–164.
5. Chung, A.K., Chua, S.E., Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J. Psychopharmacol. 25:5 (2011), 646–666.
6. Correll, C.U., Lops, J.D., Figen, V., Malhotra, A.K., Kane, J.M., Manu, P., QT interval duration and dispersion in children and adolescents treated with ziprasidone. J. Clin. Psychiatry 72:6 (2011), 854–860.
7. Correll, C.U., Robinson, D.G., Schooler, N.R., Brunette, M.F., Mueser, K.T., Rosenheck, R.A., Marcy, P., Addington, J., Estroff, S.E., Robinson, J., Penn, D.L., Azrin, S., Goldstein, A., Severe, J., Heinssen, R., Kane, J.M., Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiat. 71:12 (2014), 1350–1363.
8. Czekalla, J., Beasley, C.M. Jr., Dellva, M.A., Berg, P.H., Grundy, S., Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J. Clin. Psychiatry 62:3 (2001), 191–198.
9. Fridericia, L.S., Die Systolendauer im Elektrokardiogramm bei normaln Menschen und bei Herzkranken. Acta Med. Scand. 53 (1920), 469–486.
10. Glassman, A.H., Bigger, J.T. Jr., Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry 158:11 (2001), 1774–1782.
11. Haddad, P.M., Anderson, I.M., Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62:11 (2002), 1649–1671.
12. Harrigan, E.P., Miceli, J.J., Anziano, R., Watsky, E., Reeves, K.R., Cutler, N.R., Sramek, J., Shiovitz, T., Middle, M., A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol. 24:1 (2004), 62–69.
13. Hasnain, M., Vieweg, W.V., Howland, R.H., Kogut, C., Breden Crouse, E.L., Koneru, J.N., Hancox, J.C., Digby, G.C., Baranchuk, A., Deshmukh, A., Pandurangi, A.K., Quetiapine and the need for a thorough QT/QTc study. J. Clin. Psychopharmacol. 34:1 (2014), 3–6.
14. Johnsen, E., Aanesen, K., Sriskandarajah, S., Kroken, R.A., Loberg, E.M., Jorgensen, H.A., QTc prolongation in patients acutely admitted to hospital for psychosis and treated with second generation antipsychotics. Schizophrenia research and treatment, 2013, 2013, 375020.
15. Muscatello, M.R., Pandolfo, G., Mico, U., Lamberti Castronuovo, E., Abenavoli, E., Scimeca, G., Spina, E., Zoccali, R., Bruno, A., Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 34:1 (2014), 129–133.
16. Nielsen, J., Graff, C., Kanters, J.K., Toft, E., Taylor, D., Meyer, J.M., Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 25:6 (2011), 473–490.
17. Nose, M., Bighelli, I., Castellazzi, M., Martinotti, G., Carra, G., Lucii, C., Ostuzzi, G., Sozzi, F., Barbui, C., Star Network, G., Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study. Epidemiol. Psychiatr. Sci., 2015, 1–9 (Epub ahead of print).
18. Ozeki, Y., Fujii, K., Kurimoto, N., Yamada, N., Okawa, M., Aoki, T., Takahashi, J., Ishida, N., Horie, M., Kunugi, H., QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 34:2 (2010), 401–405.
19. Potkin, S.G., Preskorn, S., Hochfeld, M., Meng, X., A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J. Clin. Psychopharmacol. 33:1 (2013), 3–10.
20. Ramos-Rios, R., Arrojo-Romero, M., Paz-Silva, E., Carballal-Calvo, F., Bouzon-Barreiro, J.L., Seoane-Prado, J., Codesido-Barcala, R., Crespi-Armenteros, A., Fernandez-Perez, R., Lopez-Morinigo, J.D., Tortajada-Bonaselt, I., Diaz, F.J., de Leon, J., QTc interval in a sample of long-term schizophrenia inpatients. Schizophr. Res. 116:1 (2010), 35–43.
21. Ray, W.A., Meredith, S., Thapa, P.B., Meador, K.G., Hall, K., Murray, K.T., Antipsychotics and the risk of sudden cardiac death. Arch. Gen. Psychiatry 58:12 (2001), 1161–1167.
22. Ray, W.A., Chung, C.P., Murray, K.T., Hall, K., Stein, C.M., Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 360:3 (2009), 225–235.
23. Reilly, J.G., Ayis, S.A., Ferrier, I.N., Jones, S.J., Thomas, S.H.L., QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355:9209 (2000), 1048–1052.
24. Rettenbacher, M.A., Eder-Ischia, U., Bader, A., Edlinger, M., Hofer, A., Hummer, M., Kemmler, G., Weiss, E.M., Hochleitner, M., Fleischhacker, W.W., QTc variability in schizophrenia patients treated with antipsychotics and healthy controls. J. Clin. Psychopharmacol. 25:3 (2005), 206–210.
25. Sagie, A., Larson, M.G., Goldberg, R.J., Bengtson, J.R., Levy, D., An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am. J. Cardiol. 79 (1992), 797–801.
26. Sala, M., Vicentini, A., Brambilla, P., Montomoli, C., Jogia, J.R., Caverzasi, E., Bonzano, A., Piccinelli, M., Barale, F., De Ferrari, G.M., QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann. General Psychiatry, 4(1), 2005, 1.
27. Shin, H.S., Lee, W.Y., Kim, S.W., Jung, C.H., Rhee, E.J., Kim, B.J., Sung, K.C., Kim, B.S., Kang, J.H., Lee, M.H., Park, J.R., Sex difference in the relationship between insulin resistance and corrected QT interval in non-diabetic subjects. Circ. J. 69:4 (2005), 409–413.
28. Straus, S.M., Bleumink, G.S., Dieleman, J.P., van der Lei, J., t Jong, G.W., Kingma, J.H., Sturkenboom, M.C., Stricker, B.H., Antipsychotics and the risk of sudden cardiac death. Arch. Intern. Med. 164:12 (2004), 1293–1297.
29. Suzuki, Y., Sugai, T., Fukui, N., Watanabe, J., Ono, S., Tsuneyama, N., Saito, M., Someya, T., Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia. Hum. Psychopharmacol. 28:3 (2013), 215–219.
30. Takeuchi, H., Suzuki, T., Remington, G., Uchida, H., Antipsychotic polypharmacy and corrected QT interval: a systematic review. Can. J. Psychiatr. 60:5 (2015 May), 215–222.
31. van Noord, C., Straus, S.M., Sturkenboom, M.C., Hofman, A., Aarnoudse, A.J., Bagnardi, V., Kors, J.A., Newton-Cheh, C., Witteman, J.C., Stricker, B.H., Psychotropic drugs associated with corrected QT interval prolongation. J. Clin. Psychopharmacol. 29:1 (2009), 9–15.
32. Vieweg, W.V., Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. J. Clin. Psychiatry 63:Suppl. 9 (2002), 18–24.
33. Wenzel-Seifert, K., Wittmann, M., Haen, E., QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch. Arztebl. Int. 108:41 (2011), 687–693.
34. Yang, F.D., Wang, X.Q., Liu, X.P., Zhao, K.X., Fu, W.H., Hao, X.R., Zhang, X.L., Huang, G.S., Qu, S.C., Bai, J.S., Huang, X.F., Kosten, T.R., Zhang, X.Y., Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology 216:1 (2011), 9–16.
35. Yerrabolu, M., Prabhudesai, S., Tawam, M., Winter, L., Kamalesh, M., Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis. (Hagerstown, Md.) 2:1 (2000), 10–12.
36. Zarate, C.A. Jr., Patel, J., Sudden cardiac death and antipsychotic drugs: do we know enough?. Arch. Gen. Psychiatry 58:12 (2001), 1168–1171.